INDIANAPOLIS, – The EMPACT-MI phase III clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalization due to heart failure or all-cause mortality for Jardiance® (empagliflozin) versus placebo, which did not reach statistical significance. Jardiance was initiated in adults within 14 days of an acute myocardial infarction, commonly known as a heart attack, and …
AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August 2023, which includes data highlighting the opportunities for improved management in heart failure (HF), and AstraZeneca’s leadership across the interconnectedness of chronic diseases. Among these abstracts will be sub-analyses from the DELIVER trial – a trial …
